Day 2 - 2023 agenda. The 2024 agenda will be published soon. - CET/CEST (Cent Europe Summer, GMT+2)
Day 2 - 2023 agenda. The 2024 agenda will be published soon. - CET/CEST (Cent Europe Summer, GMT+2)
Location: Room Barcelona
This session dives into the ever-evolving landscape of dealmaking and VC investment and unravels the forces reshaping the industry's dynamics. Hear real-world case studies and expert insights on strategies for forging strategic alliances, securing partnerships, investing in and driving innovation, to address the healthcare challenges of the future. Whether you're a pharmaceutical executive, investor, or innovator, this session navigates the intricacies of dealmaking and provides guidance for success, in this transformative era.
- Christopher Maggos - Managing Director, Cohesion Bureau
- Bradley Hardiman - Senior Director, Astellas Venture Management
- Philippe Lopes-Fernandes - Executive VP, CBO, IPSEN
- Detlev Mennerich - SVP, Global Head of Business Development & Licensing, Boehringer Ingelheim
- Erica Horwitz - VP, Mergers & Acquisitions, Bristol-Myers Squibb
- Matthias Müllenbeck - SVP, Head Global Business Development & Alliance Management, Merck KGaA
Location: Room Barcelona
This session evaluates the strategies around late-stage deal-making, when M&A is more suitable than licensing, the role of late-stage when building a sustainable pipeline, why Ipsen is interested in late-stage and why biotech’s should do late-stage deals. Further, unravel the key stages of the process through the case study of Albireo and understand the pre-deal steps, peri-deal (transition etc.) and post-deal considerations based on environmental changes.
- Linda Pullan - Founder, Pullan Consulting
- Jean-Patrick Hennebelle - SVP, Head of Global Late-Stage Partnering, IPSEN
Location: Room Barcelona
Join experts from Johnson & Johnson Innovation and Evotec as they debate the benefits and challenges of open innovation between companies. They will share their views on the vital ingredients for partnerships and strategies that lead to enduring relationships between companies, and review the trends and market dynamics that are shaping the R&D landscape and could impact future shared R&D models in life sciences.
- Bernd Mühlenweg - SVP of Global Business Development (Missions), Evotec
- Matthias Evers - CBO, Evotec
- Sonal Patel - VP of Oncology Scientific Innovation, Johnson and Johnson Innovation
- Prabhu Velusami - Senior Director, Early Innovation Partnering (Retina & Data Sciences), Johnson & Johnson Innovation
Location: Room Stockholm
In this session, the panelists will explore the latest trends and developments in oncology. They will also share insights on successful deal-making in the space, with a particular focus on the creating effective partnerships between the (small) biotech players and pharma heavyweights (companies)
- Lucie Ellis-Taitt - Executive Director - In Vivo, Citeline
- Jean-Paul Kress - CEO, MorphoSys
- Susanne Schaffert - Board Director, Novo Holding, Incyte, Galapagos, Vetter, ARTBio
Location: Room Stockholm
This session delves into the landscape of Cell and Gene Therapy (C>) with a focus on its current status and emerging trends. Experts will share valuable insights into the opportunities and challenges confronting C>, shedding light on its promising potential. The discussion will also spotlight the legislative and procedural aspects involved in bringing C> innovations to market, with emphasis on Europe. Ultimately, this session aims to ensure accessibility for those in need, while shaping the future of the life science industry.
- Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate
- Miguel Forte - CEO, Kiji Therapeutics
- Lutz Bonacker - SVP and General Manager of Commercial Operations Europe, CSL Behring
- Daniel Forler - Director Business Development, Bayer Pharmaceuticals
Location: Exhibit Hall Stage
This session will explore the rise in close collaborations between CROs and other Service Providers with the Venture Capital and Fundraising/Partnering community. The panel will discuss how biotech's are benefitting from these collaborations through: better early engagement, development planning, scientific and therapeutic advice, and budget forecasting. Finally, we will discuss how these collaborations are helping biotech's achieve their fundraising and partnering goals.
- Brandon Early - VP Project Delivery, ICON plc
- Linus Lin - Manging Director, Chorus, Eli Lilly and Company
- Stefan Luzi - Partner, Gilde Healthcare
Location: Exhibit Hall Stage
From 2025, a centralized clinical evaluation of new pharmaceuticals will take place in the European Union (EU). The new procedure is a milestone, because until now reimbursement has been exclusively at the level of the individual member states of the EU. Although initial reimbursement and pricing will remain in the hands of the individual EU countries, the future centralized clinical evaluation will provide a uniform basis for reimbursement decisions in the individual EU countries. The new procedure is therefore one of the most far-reaching innovations in EU pharmaceutical legislation for decades. This talk will focus on how companies with innovative products can best prepare for the new procedure. What do I have to do today to ensure that my product finds its way to patients in the EU from 2025? How do I have to set up my clinical studies now so that they meet the new requirements? What points are still open?
- Fabian Berkemeier - Managing Director, IGES Institute
- Kevin Rieger - Director Corporate Affairs Germany, BeiGene
Location: Exhibit Hall Stage
This talk will focus on the solutions and lessons learned to overcome supply chain challenges, which were documented during and post pandemic, that lead to the issue of two draft guidance's by the FDA, asking for risk mitigation plans. This session will uncover how to ensure supply and reduce bottlenecks by
establishing mitigation and business continuity plans, that include a global supply chain network with a dual sourcing strategy, from a 30,000 and 10,00 feet perspective.
- Benjamin Minow - Managing Director, WuXi Biologics Germany
Location: San Sebastian
10:15 – 10:30 Immuneering Corporation Oncology
10:30 – 10:45 Insilico Medicine Oncology
10:45 – 11:00 InSphero Oncology
11:00 – 11:15 Jaguar Health, Inc. Oncology
11:15 – 11:30 Theriva Biologics, Inc. Oncology
11:30 – 11:45 WMT AG Oncology
11:45 – 12:00 ZTI Biosciences Oncology
Location: Exhibit Hall Stage
Learn everything you need to know to power up your partnering! This session is for delegates new to partnering. In this workshop, we will go over what you can expect out of partnering and what others will expect from you. We will provide an overview of the platform and discuss principles around timing and best practices to get the most out of partneringONE. Come away from the session with a clear understanding of what you can do to generate the best return on investment from partnering, at this and future events.
Location: Room Barcelona
This ever-popular session takes a deep dive into the current state of the life sciences industry with the expertise of today’s leading pharma dealmakers and venture investors. Join this engaging discussion to learn how to navigate the current climate of the biotech industry.
- Anton Gueth - Managing Director, EVOLUTION Life Science Partners
- Evonne Sepsis - Managing Director, ESC Advisors
- Guillaume Vignon - Global Head BD&L Transactions, Novartis
- John McDonald - Corporate VP, Head of Business Development and M&A, Novo Nordisk
- Graziano Seghezzi - Managing Partner, Sofinnova Partners
Location: Room Barcelona
In today's dynamic pharmaceutical landscape, optimizing asset utilization is pivotal for sustained growth and innovation. This session explores how pharmaceutical companies can create substantial value by externalizing deprioritized assets to biotech partners and actively participating in the innovation ecosystem. We delve into the transformative power of data mining, asset repositioning, and the strategic integration of Artificial Intelligence (AI) in out-licensing activities. Join us as we navigate the evolving landscape of pharma-biotech collaborations, unveiling new avenues for generating value, fostering innovation, and reshaping the future of healthcare.
- Begona Carreno - Chief Business Development Officer, Vectura Fertin Pharma
- Peter Dolan, Ph.D., J.D. - Director, Global Out-Licesning, Sanofi
- Sandra von Meier - Head of Business Development & Licensing, Debiopharm
- Ji Li - Principal, JL Biopharma Consulting
Location: Room Barcelona
Translational Funds represent an exciting development in the European venture capital landscape, as they provide a unique funding and support mechanism for startups at the intersection of science and entrepreneurship. Funds invest in the most exciting innovative biotech projects originated at top class universities and research institutes across Europe.
- Ed Saltzman - Senior Strategic Advisor, Lumanity
- Ingrid Kelly - Partner, Xista Science Ventures
- Bert Klebl - Managing Director, Khanu Management GmbH
- Jaromir Zahrádka - CEO and Managing Partner, i&i Biotech Fund I
- Stefaan Allemeersch - Executive Director, Centre for Drug Design & Discovery (CD3)
- Martin Raditsch - Managing Director, CARMA Fund Management GmbH
Location: Room Barcelona
As the new era begins to redefine the structure of fundraising, a stronger relationship between the pharmaceutical industry and early-stage investors has formed. Join this session to discover the dynamic between the pharmaceutical cooperate venture arms and investors, the benefits that the partnership offers, and how it proves to be an effective strategy for pharma to tap into early-stage companies which are driving innovation in the life sciences ecosystem.
- Stefan Fischer - Managing Partner, TVM Capital Life Science
- Brad Robling - VP Lilly New Ventures, Eli Lilly and Company
- Christian Stiebner - Senior Investment Manager, KfW Capital
- Cedric Bisson - Partner, Teralys Capital
- Sonya Pauls - Partner, Clifford Chance
Location: Room Barcelona
Join us for a conversation between VC industry veterans and emerging VCs about the pitfalls in biotech, the lessons learnt and how to stay passionate, followed by drinks.
- Vanessa Carle - Associate, Forbion
- Christoph Kocher - Senior Associate, GIMV
- Rianne Ellenbroek - Principle, BGV (BioGeneration Ventures)
- Andreas Jurgeit - Partner, Life Sciences, GIMV
- João Ribas - Principal, Novo Holdings
- Rebecca Canter - Senior Director - Venture Sciences, Eli Lilly and Company
Location: Exhibit Hall Stage
To what degree can biotech industry implement business models from other industries such as the semiconductor industry to accelerate advanced biomanufacturing?- IMEC model of manufacturers-equipment-materials- new models of cooperation in drug development?- value chain model to cooperate with academics & university hospitals and other actors?- how to support new ideation and newcos?- what are the differences with e.g. semi? e.g. clinical trials? patients? GMP?
- Pieter De Maeght - Science & Technology Counselor, Flanders Investment & Trade
- Jan Wauters - Science & Technology Counselor, Flanders Investment & Trade
- Urmi Prasad Richardson - President, EMEA, Thermo Fisher Scientific
Location: Exhibit Hall Stage
Introduction of the first three waves of biologics manufacturing: Biologics manufacturing has undergone three waves since the 1980s, driven by biologics technological innovation and socio-economic development. These three waves of biologics manufacturing differentiate themselves by their technology platform, facility capacity scale, and mode of operation.
Challenges of continuous global manufacturing capacity gap and the rise of the 4th revolutionary wave of biologics manufacturing: With a broader global biologics market, increasing demand, and explosion of new products, the problem of capacity shortages in biologics manufacturing has become increasingly prominent. The capacity gap in EU & US reached 5.3 million litres in 2021, and there is a gap of 15-25 million litres in China by 2030 (with current capacity of only 1.84 million litres). Large-scale commercial production based on CDMOs has become an industry trend. These factors entail a 4th wave of biologics manufacturing, symbolized by 30,000-liter ultra-large scale technology and million-litre total capacity Mega-factory in the CDMO model.
- Peng Jiao - President & CEO, BiBo Biopharma Engineering Co., Ltd.
Location: Exhibit Hall Stage
- A Tale of Irish Biopharma: The Evolution of One of the Leading Global Biopharma Hubs
- Growth of the Sector: Creating an Ecosystem with the National Institute for Bioprocessing Research and Training (NIBRT)
- Innovation-driven culture: collaboration between enterprise, academia, and government
- Ready for the Future: Digitization and Cell and Gene Therapies
- Why Ireland for you?
- Vishal Dakhole - VP Life Sciences - Germany & Northern Europe, IDA Ireland
- Gillian Lawless - Head New Business & Marketing, BioPharma, IDA Ireland
Location: Exhibit Hall Stage
Lifesciences is one of the most globalized sectors so, how do you drive innovation and support development from a more regional/local point of view? In this session, the panelist will share the different drivers of innovation and how in their respective ecosystems, they are able to scale up the innovations at a global scale. The question of the impact of these innovations will also be addressed, in terms of concrete economic and social returns. Other key topics that will be covered within this session include talent attraction, investments, scale up support and the cluster's catalyser's role.
For all those present, this session will be followed by the opportunity to grab a drink, network and follow up the conversation.
- Anaïs Le Corvec - Managing Director, Council of European BioRegions asbl
- Tero Piispanen - Senior Executive, Turku Science Park
- Amel Tounsi - CEO, Bridge2Health (B2H)
- Margot Jehle - Project Manager, BioRegio STERN Management GmbH
Location: Stockholm
During this session, panelists will discuss the essential ingredients that need to be brought to the table, from both sides, to cook together and form a partnership/ successful collaboration, along with the lessons learned.
- Juliette Lemaignen - Partner, Inartis Foundation
- Regina Hodits - Managing Partner, Wellington Partners
- Peter Nell - Co-founder and CEO, Stealthmode Company
- Ben Panter - Founder & CEO, Blackford Analysis
- Isabelle Scarabin - Business Licensing Officer, Bayer
Location: Stockholm
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe audience. A panel of esteemed judges will evaluate the pitches and select the winners.
Sponsored by: Bayer
Startup Spotlight Presenters: *In order
- Jan-Philipp Kruse - Senior Director BD&L & OI - Lead Bayer Co.Lab, Bayer Pharmaceuticals
- Jörg Knäblein - Scientific Finder Collaborate to Cure Hub EMEA, Bayer Pharmaceuticals
- Christoph Broja - Managing Director, EQT Life Sciences
- Carolin Clement - Head of Unit Biotech and Pharma, Berlin Partner for Business and Technology
Location: San Sebastian
12:00 – 12:15 NEX-I Oncology
Location: San Sebastian
13:00 – 13:15 Accession Therapeutics Limited Immuno-Oncology
13:15 – 13:30 Aptevo Therapeutics Inc. Immuno-Oncology
13:30 – 13:45 Elpiscience Biopharma Immuno-Oncology
13:45 – 14:00 Epsilogen Immuno-Oncology
14:00 – 14:15 QBiotics Immuno-Oncology
14:15 – 14:30 LIfT BioSciences Immuno-Oncology
Location: San Sebastian
14:30 – 14:45 Accelerated Biosciences Corp. Cell & Gene Therapies
14:45 – 15:00 EG 427 Cell & Gene Therapies
15:00 – 15:15 ENCell Co., Ltd. Cell & Gene Therapies
Location: San Sebastian
16:15 – 16:30 Immunis Inc. Cell & Gene Therapies
16:30 – 16:45 Lumosa Therapeutics Cell & Gene Therapies
16:45 – 17:00 Genprex, Inc. Cell & Gene Therapies
17:00 – 17:15 Regend Therapeutics Cell & Gene Therapies
Location: Exhibit Hall Stage
Learn everything you need to know to power up your partnering! This session is for delegates familiar with partnering who want to take their partnering practice to the next level. This session will go over specific tools and top tips for collaborating with colleagues, saving time, as well as increasing response rates and acceptance rates. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events.
Location: Exhibit Hall Stage
Experience how a few breaths and stretches can de-stress you in just a few minutes.
Take a moment to exhale and move your body.
Calm your mind and feel the difference.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Standing and seated (chair) exercises only.
Location: Exhibit Hall Stage
Experience how a few breaths and stretches can de-stress you in just a few minutes.
Take a moment to exhale and move your body.
Calm your mind and feel the difference.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Standing and seated (chair) exercises only.